Ptc Therapeutics (PTCT) EBT Margin (2016 - 2025)
Historic EBT Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 10.94%.
- Ptc Therapeutics' EBT Margin rose 388600.0% to 10.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.4%, marking a year-over-year increase of 1004100.0%. This contributed to the annual value of 74.22% for FY2024, which is 94600.0% up from last year.
- According to the latest figures from Q3 2025, Ptc Therapeutics' EBT Margin is 10.94%, which was up 388600.0% from 39.72% recorded in Q2 2025.
- Ptc Therapeutics' 5-year EBT Margin high stood at 79.06% for Q1 2025, and its period low was 154.99% during Q4 2024.
- Its 5-year average for EBT Margin is 71.64%, with a median of 82.92% in 2021.
- Per our database at Business Quant, Ptc Therapeutics' EBT Margin surged by 1399900bps in 2021 and then tumbled by -749700bps in 2024.
- Ptc Therapeutics' EBT Margin (Quarter) stood at 83.89% in 2021, then tumbled by -38bps to 115.48% in 2022, then soared by 31bps to 80.01% in 2023, then tumbled by -94bps to 154.99% in 2024, then surged by 93bps to 10.94% in 2025.
- Its EBT Margin was 10.94% in Q3 2025, compared to 39.72% in Q2 2025 and 79.06% in Q1 2025.